Fig. 7

Guadecitabine/ICBs significantly reduce tumor nodules formation in the lung of C57black/6J mice. A schedule of treatments: B16F10 cells were injected IV on day 0 (black arrow), guadecitabine or vehicle were given IP daily from day +1 to day +15 (black line), ICBs or Isotype controls (Antibodies) were given IP on days +2, +5, +8, +11, +14 (red arrow). B Mice lungs were FFPE and mounted on microscope slides. The histograms show the comparison among each group of treatment concerning: the numbers of lung micronodules (left panel), the mean of nodules maximum diameters (middle panel) and the percentage of lung area occupied by tumor (right panel) (Sample sizes: Ctrl n=6, guadecitabine n=3, guadecitabine/ICBs n=6, ICBs n=3). C The histogram shows the percentages of mice bearing extra-lung metastases for each group of treatment (Sample sizes: Ctrl n=15, guadecitabine n=10, guadecitabine /ICBs n=15, ICBs n=10). D Representative images of lungs for each group of treatment. *p<0.05, **p<0.02, ***p<0.01, ****p<0.001